REPLIGEN CORP Form 8-K August 28, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 22, 2013

REPLIGEN CORPORATION

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction

0-14656 (Commission 04-2729386 (IRS Employer

of incorporation) File Number) Identification No.)

Edgar Filing: REPLIGEN CORP - Form 8-K

41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453
(Address of principal executive offices) (Zip Code)
Registrant s telephone number, including area code (781) 250-0111

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):	
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: REPLIGEN CORP - Form 8-K

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 22, 2013, Repligen Corporation (the Company) and Jonathan I. Lieber agreed to terminate Mr. Lieber s employment with the Company without Cause (as such term is defined in Mr. Lieber s Employment Offer Letter, dated September 20, 2012), effective as of the close of business on August 23, 2013.

Edgar Filing: REPLIGEN CORP - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REPLIGEN CORPORATION

Date: August 28, 2013

By: /s/ Walter C. Herlihy

Walter C. Herlihy

President and Chief Executive Officer